Abstract
G A A b st ra ct s 76 years old), 50 pts (20 %) were current smokers, 81 pts (33%) had a prior psychiatric diagnosis reported in the medical record (57 depression, 17 anxiety disorder, 1 bipolar disorder, 4 other). 77 pts (31 %) were on prednisone, 46 pts (19 %) were on budesonide, and 125 pts (51 %) were on an immunomodulator. Median follow up was 279 days (range 56, 693 days). 33 pts (13 %) were noncompliant in follow up. 60 pts (24%) had at least moderate depressive symptoms at baseline (PHQ > 10). Depressive symptoms at baseline were significantly associated with noncompliance in follow up (Hazards ratio 2.28, CI 1.14.6, p<0.05). Psychiatric history, age, sex, and disease type were not significantly associated with noncompliance in follow up. Conclusion Depressive symptoms at baseline were associated with medication noncompliance of anti-TNF therapies at follow up when controlling for age, sex, disease type and history of psychiatric disease. Addressing depressive symptoms at medication initiation may be an important factor in ensuring compliance.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
